Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. View (RXRX) real-time stock price, chart, news, analysis, analyst reviews and more.

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly. This price reflects trading activity during the overnight session on the Blue Ocean ...